Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
7.99
-0.31 (-3.68%)
Mar 31, 2025, 1:27 PM EDT - Market open
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 130 employees as of December 31, 2024. The number of employees decreased by 170 or -56.67% compared to the previous year.
Employees
130
Change (1Y)
-170
Growth (1Y)
-56.67%
Revenue / Employee
$1,808,715
Profits / Employee
$44,246
Market Cap
1.10B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AUPH News
- 4 weeks ago - Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga
- 4 weeks ago - Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - Business Wire
- 5 weeks ago - Aurinia Pharmaceuticals: There's Still Time For Sales Growth - Seeking Alpha
- 5 weeks ago - Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Business Wire
- 2 months ago - 3 Biotech Stocks With Notable Insider Buying - Seeking Alpha
- 4 months ago - Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire
- 4 months ago - Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - Business Wire